

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Final draft guidance

# Deuruxolitinib for treating severe alopecia areata

## 1 Recommendations

- 1.1 Deuruxolitinib can be used, within its marketing authorisation, as an option to treat severe alopecia areata in adults. Deuruxolitinib can only be used if the company provides it according to the commercial arrangement (see [section 2](#)).
- 1.2 Use the least expensive option of the suitable treatments (including deuruxolitinib and ritlecitinib), having discussed the advantages and disadvantages of the available treatments with the person with the condition. Take account of administration costs, dosages, price per dose and commercial arrangements.

## What this means in practice

Deuruxolitinib must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option. Deuruxolitinib must be funded in England within 30 days of final publication of this guidance.

There is enough evidence to show that deuruxolitinib provides benefits and value for money, so it can be used routinely across the NHS in this population.

## Why these recommendations were made

Usual treatment for severe alopecia areata in adults is ritlecitinib. Deuruxolitinib works in a similar way.

Clinical trial evidence shows that deuruxolitinib is more effective than placebo at improving hair regrowth. Deuruxolitinib has not been directly compared with ritlecitinib in a clinical trial. The results of an indirect comparison are uncertain but suggest that deuruxolitinib is likely to work as well as ritlecitinib.

A CYP2C9 genotyping test is needed before starting deuruxolitinib. The company has stated that it will cover the costs associated with the test. Taking this into account, the costs are similar for deuruxolitinib and ritlecitinib. So, deuruxolitinib can be used.

For all evidence, see the [committee papers](#). For more information on NICE's evaluation of ritlecitinib, see the committee discussion section in [NICE's technology appraisal guidance on ritlecitinib for treating severe alopecia areata in people 12 years and over](#).

## 2 Information about deuruxolitinib

### Marketing authorisation indication

- 2.1 Deuruxolitinib (Leqselvi, Sun Pharmaceuticals) is indicated for 'the treatment of adult patients with severe alopecia areata'.
- 2.2 The dosage schedule is available in the [summary of product characteristics for deuruxolitinib](#).

### Price

- 2.3 Deuruxolitinib costs £949.41 per pack of 60x8 mg tablets (company submission).
- 2.4 The company has a commercial arrangement (simple discount patient access scheme). This makes deuruxolitinib available to the NHS with a discount. The size of the discount is commercial in confidence.

### Sustainability

- 2.5 Information on the Carbon Reduction Plan for UK carbon emissions for Sun Pharmaceuticals will be included here when guidance is published.

### 3 Implementation

- 3.1 Section 7 of the [National Institute for Health and Care Excellence \(Constitution and Functions\) and the Health and Social Care Information Centre \(Functions\) Regulations 2013](#) requires integrated care boards, NHS England and, with respect to their public health functions, local authorities to comply with the recommendations in this evaluation within 90 days of its date of publication. Because deuruxolitinib has been recommended through the [cost-comparison process](#), NHS England and integrated care boards have agreed to provide funding to implement this guidance 30 days after publication.
- 3.2 The Welsh ministers have issued directions to the NHS in Wales on implementing NICE technology appraisal guidance. When a NICE technology appraisal guidance recommends the use of a drug or treatment, or other technology, the NHS in Wales must usually provide funding and resources for it within 60 days of the first publication of the final draft guidance.
- 3.3 When NICE recommends a treatment ‘as an option’, the NHS must make sure it is available within the period set out in the paragraphs above. This means that, if a patient has severe alopecia areata and the healthcare professional responsible for their care thinks that deuruxolitinib is the right treatment, it should be available for use, in line with NICE’s recommendations.

### 4 Evaluation committee members

The [highly specialised technologies evaluation committee](#) is a standing advisory committee of NICE. This topic was considered as a cost-comparison evaluation by the chair and vice chair of the [highly specialised technologies evaluation committee](#).

Committee members are asked to declare any interests in the technology being evaluated. If it is considered there is a conflict of interest, the member is excluded from participating further in that evaluation.

## **Chair**

### **Paul Arundel**

Chair, highly specialised technologies evaluation committee

## **NICE project team**

Each evaluation is assigned to a team consisting of 1 or more health technology analysts (who act as technical leads for the evaluation), a technical adviser, a project manager, and an associate director or principal technical adviser.

### **Emma Bajela**

Technical lead

### **Caron Jones**

Technical adviser

### **Jennifer Upton**

Project manager

### **Lizzie Walker**

Principal technical adviser

ISBN: [to be added at publication]